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Accepted 8 March 2017Background: There are high levels of prescription and consumption of prescription opioids in the US. Misuse of
prescription opioids has been shown to be highly correlatedwith prescription opioid-relatedmorbidity andmor-
tality including fatal and non-fatal overdose. We characterized the past-year prevalence of prescription opioid
misuse among those 11–30 years of age in the US.
Methods: A systematic review and meta-analysis were carried out following a published protocol and PRISMA
guidelines. We searched electronic databases; reports were eligible if they were published between 1/1/1990–
5/30/2014, and included data on individuals 11–30 years of age from the US. Study quality was assessed using
the Newcastle-Ottawa Scale.
Results: A total of 3211 abstracts were reviewed for inclusion; after discarding duplicates and identifying non-el-
igible reports, a total of 19 unique reports, providing 34 estimates, were included in the final systematic review
andmeta-analysis. The range of past-year prescription opioidmisuse prevalence the reports was 0.7%–16.3%. An
increase in prevalence of 0.4% was observed over the years of data collection.
Conclusions: This systematic review and meta-analysis found a high prevalence of past-year prescription opioid
misuse among individuals 11–30 years of age. Importantly, we identified an increase in past-year prevalence
1990–2014. Misuse of prescription opioids has played an important role in national increases of fatal and non-
fatal drug overdose, heroin use and injection, and HIV and HCV infection among young people. The observed
high and increasing prevalence of prescription opioid misuse is an urgent public health issue.
© 2017 Elsevier Inc. All rights reserved.Keywords:
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Meta-analysis1. Introduction
There are high levels of prescription and consumption of prescrip-
tion opioids in the US. The US market accounts for nearly 100% of the
world's hydrocodone and roughly 80% of the global consumption of
oxycodone (INCB, 2008). Since 1990, prescriptions of opioids tripled
globally; in the United States, prescribing of opioids has risen 350%
since 1999 and the per capita dispensing of prescription opioids rose
from 73.6 to 369.3 mg per person per year between the mid-1990s
and mid-2000s (Fischer, Keates, Buhringer, Reimer, & Rehm, 2014;munodeficiency virus.
ing, Center forDrugUse andHIV
, New York, NY 10010, UnitedImtiaz, Shield, Fischer, & Rehm, 2014; Katz et al., 2007; Rosenblatt &
Catlin, 2012; SAMSHA, 2011). Non-medical prescription opioid con-
sumption has been demonstrated to be highly correlated with prescrip-
tion opioid-related morbidity andmortality (including substance abuse
treatment admissions and fatal and non-fatal overdose) (Green et al.,
2013; Imtiaz et al., 2014; Tanne, 2013). In 2013, 37% of drug overdose
deaths in the US were attributed to prescription opioids in the US (He
et al., 2013). Sales of prescription opioids, associated deaths, and treat-
ment admissions have increased proportionally (CDC, 2012a; Imtiaz et
al., 2014).
In the past decade, the prevalence of past-year non-medical pre-
scription opioid use has risen to almost 5% among the general US popu-
lation (Imtiaz et al., 2014). Among adolescents and young adults, the
prevalence of lifetime and past-year use has also risen. From the early
1990s to the early 2000s, the rate of misuse rose from 12 to 13 per
1000 persons to 30–50 per 1000 persons among those 12 to 25 years
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timated to have misused prescription opioids (Fiellin, Tetrault, Becker,
Fiellin, & Hoff, 2013). A recent national survey of suburban adolescents
and early adults reported that one-third had misused prescription opi-
oids by the age of 21 (Catalano, White, Fleming, & Haggerty, 2011). In
response to such data, the White House announced initiatives and pro-
posed funding to expand prescription drug monitoring and access to
drug abuse treatment (The White House, 2016).
There have been no systematic reviews that have addressed past-
year prescription opioid misuse among those 30 years of age and youn-
ger in the US nor have there been efforts to quantify the prevalence of
misuse among this age group in meta-analysis. Use and misuse of pre-
scription opioids at younger ages has been found to be associated with
a higher likelihood of a diagnosis of opioid abuse/dependence (Edlund
et al., 2010; McCabe, West and Wechsler, 2007; McCabe, West,
Morales et al., 2007). Therefore, the need to synthesize and quantify
the burden of misuse among this population is critical for informing
public health interventions and resource allocation to address prescrip-
tion opioid misuse in adolescence and young adulthood.
The objective of this systematic review and meta-analysis was to
synthesize the data on the prevalence of prescription opioid misuse
among those 11–30 years of age in the US. Drug use trends among ado-
lescents and young adults up to age 30 – the ages when misuse is more
likely to lead to abuse or dependence – foreshadows future trends in
problem drug use (McCabe, West, Morales, Cranford, & Boyd, 2007;
Toumbourou et al., 2007).
2. Methods
Data presented in this paper were collected as part of a series of
linked systematic reviews of the HCV Synthesis Project. The aim of the
HCV Synthesis Project is to synthesize burden of disease data on both
key populations of incipient risk for HCV acquisition (e.g., persons
who misuse prescription opioids) and populations with persistent,
long-standing HCV epidemics (e.g., persons who inject drugs) in an ef-
fort to inform evidence-based policy to address preventable morbidity
and mortality due to HCV infection.
Methods of data collection and extraction are presented elsewhere
(Jordan, Des Jarlais, & Hagan, 2014); as such, only a summary is present-
ed here. The study protocol was also registered with the International
Register of Prospective Systematic Reviews (PROSPERO; registration
number 42014008870). The methods of this study follow PRISMA
guidelines (Shamseer et al., 2015).
2.1. Search strategy
Amedical librarian was consulted for the development of the search
strategy. Automated searches were carried out with the use of a sensi-
tive search string with keywords including prescription opioid misuse,
in the following electronic bibliographic databases and citation indices:
PubMed, Ovid MEDLINE, Web of Knowledge, and PsychINFO. Manual
search methods were also used and included hand-searches of public
health and medical conference databases and reference lists of reviews
and related articles for relevant reports, abstracts or presentations.
2.2. Inclusion criteria
Reportswere considered for eligibility if theywere: 1) published be-
tween 1/1/1990 and 5/30/2014; 2)were in English (no potentially eligi-
ble, non-English language reports were encountered); 3) included
measures of prevalence of prescription opioid misuse or prescription
opioid abuse, dependence or substance use-related disorder as defined
by the DSM-IV criteria; and 4) report prevalence among adolescents
and young adults aged 11–30 years. All reports were required to report
data on prevalence of prescription opioidmisuse in the past 12months;
reports that provided prevalence data for any other timeframe wereexcluded. Review of potentially eligible reports was a multi-step pro-
cess; this process is depicted in the PRISMA flow diagram of Fig. 1. An
abstract screening pilot was conducted where both the Project Director
(PD, AEJ) and the principal investigator (PI, HH) reviewed several sets of
abstracts and compared exclusion/inclusion results; pilots were carried
out until consensus between reviewers was reached and there was
100% agreement. In the final abstract screening, the PD and PI each
reviewed one half of the abstracts.
2.3. Data extraction
Two researchers carried out data extraction. Aswith abstract screen-
ing, a pilot procedure was donewith the data extraction process to both
refine the data extraction form and to ensure 100% agreement between
data extractors with respect to which data were eligible for extraction.
All data extraction was reviewed by the PD for completeness and to
field questions that emerged during data extraction. Any unresolved is-
sueswere discussed to reach consensus, andwhen necessary, the PIwas
brought in to discuss issues related to methodology and study design.
Data were extracted onto coding forms that included items related
to study methods and characteristics of the sample. Study years, loca-
tion and description of location (e.g., population density), study design
elements, and characteristics of the study sample were abstracted
from each report. Prevalence, measures of variance (e.g., confidence in-
tervals), and crude and adjusted measures of association between mis-
use and exposures examined in each report were extracted.
2.4. Quality ratings
Assessments for report-level quality were informed by the Newcas-
tle-Ottawa Scale (NOS) (Wells et al., 2009). In an effort to reduce the
likelihood of introducing bias with respect to misclassification of the
outcome, we employed strict entry criteria requiring that studies pres-
ent data prescription opioid misuse in the past one year. For this analy-
sis, our emphasiswas on assessing the risk due to selection bias due that
may arise from methods to sample study participants. Thus, quality as-
sessment was a one domain dichotomous variable where reports were
either classified as being of higher quality and lower risk of selection
bias if they employed probability or other non-probability weighted
systematic sampling methods, and of lower quality and higher risk of
selection bias if convenience sampling was employed.
Misclassification of the outcome of interest, prescription opioid mis-
use, was also of particular importance to this study. In order to account
for variability in the defining of prescription opioidmisuse in the includ-
ed reports, we recorded the studies' definitions of misuse (e.g., “use of
medication that was not prescribed to the individual or use only for
the experience or feeling it causes”), and classified reports by their op-
erational definitions (Katz et al., 2007). Throughout this report we use
the term “misuse” to characterize all prevalence data.
2.5. Data analysis
We first sought to determine an overall pooled prevalence of pre-
scription opioid misuse among all the included reports. We calculated
95% confidence intervals (CIs) around the pooled prevalence estimates
assuming a normal distribution. Cochran's Q statistic was calculated to
ascertain whether or not heterogeneity was observed across estimates
andwhether the heterogeneity was compatible with chance. I2 was cal-
culated to quantify inconsistency in the prevalence measures. Meta-re-
gression was conducted to estimate the prevalence of prescription
opioid misuse over time. Analyses were conducted using both R and
SPSS (version 23.0) (Blasiole, Shinkunas, Labrecque, Arnold, &
Zickmund, 2006; IBM Corp, 2013; R Development Core Team, 2008).
Data synthesis began with the search for homogeneous subsets
across included reports. Examinations of study-level covariateswere ul-
timately limited by the available information presented in each study.
Fig. 1. PRISMA flow of information from identification to inclusion of studies.
33A.E. Jordan et al. / Journal of Substance Abuse Treatment 77 (2017) 31–37Lack of consistency in the reporting of covariates was also a limiting fac-
tor. However, calendar time, geographic region, and selection bias could
be examined as study-level moderators.
When reports presented data collected across a number of years,
spans of 4 years or less were assigned a temporal midpoint for the peri-
od of data collection in analyses of changes in prevalence over time. The
assignment of a temporal midpoint to reports that presented data over
multiple year periods permitted us to include these estimates, along
with estimates reported in individual years, in moderator analyses.
3. Results
3.1. General findings
After conducting both an automated and manual search, a total of
3211 abstracts were reviewed for duplicates; and after removing 1933
duplicate abstracts, 1278 were screened for initial eligibility. Fig. 1 de-
picts the process of abstract and full-text review. A total of 19 reports,
including 34 independent non-overlapping estimates of prevalence,
reflecting 503,845 unique participants, met the inclusion criteria and
were included in this review. In total, the 19 reports provided 34 sepa-
rate estimates of prescription opioid misuse. 18 estimates presented
data for a single year. 17 estimates presented data over a range of
years; there estimates were assigned a midpoint in calendar time
analysis.
Of the 34 estimates, 21 estimates were derived from probability
samples. Eight reports presented data using probability survey
methods, and the remaining 11 reports presented data using other
methods such as convenience or systematic sampling in observational
research. Table 1 depicts the included estimates by sampling method.
3.2. Prevalence of past-year prescription opioid misuse
The range of past-year prescription opioidmisuse prevalence among
the19 reportswas 0.7%–16.3%. Fig. 2 presents a Forest Plot of the reportsordered by prevalence (with 95% confidence intervals). Reports pre-
senting data from probability-based surveys presented a range of prev-
alence estimates from 3.9–12.7% and non-probability samples
presented a range of prevalence estimates from 0.7–16.3%. There was
significant heterogeneity (I2 = 99.61%; Q-statistic = 7619.34, p-value
b0.0001) in the data; efforts were made to address heterogeneity sepa-
rating the data based on similar sampling method (I2 = 99.48%; Q-sta-
tistic = 2505.65, p-value b0.0001, for probability samples, and I2 =
99.63%; Q-statistic = 1666.05, p-value b0.0001 for non-probability
samples). We attempted to address high heterogeneity by examining
studies by study location. Therewere 13 estimates that providedmisuse
data from education settings (e.g., high school, college); these estimates
had a pooled prevalence of 7.39% (95% CI 5.84–8.94). Again, high het-
erogeneity was present (I2 = 99.13%; Q-statistic = 950.16, p-value
b0.0001) which reflects the high variability as shown by the wide con-
fidence intervals (Table 1). Given high heterogeneity, we were not able
to pool prevalence estimates; therefore we present the range of preva-
lence estimates from probability and non-probability samples.
Individual reports using probability sampling generally had
narrower confidence intervals for their estimates of prevalence than
non-probability based reports due to larger sample sizes (n range
236–11,521). The probability-based samples were predominately na-
tional household surveys; in contrast, the reports employing non-prob-
ability sampling were typically smaller (n range 20–543), recruited
from community settings and these had higher variability in estimates.
Eleven different definitions of prescription opioid misuse were used
in 19 reports; however, these definitions differed only slightly. The Na-
tional Survey on Drug Use and Health (NSDUH) definition (“Have you
ever, even once, used a prescription pain reliever that was not pre-
scribed for you or that you took only for the experience or feeling it
caused?”) was the most frequently used definition (n = 8 estimates in
5 reports) (Table 1). Given the variability in misuse definition there
was no meaningful way to statistically examine the extent to which
misclassification bias may or may not have affected the prevalence esti-
mates as a function of definition of prescription opioid misuse.
Table 1
Prevalence of past-year prescription opioid misuse among those 11–30 years of age in the United States.
Report
Year of
data
collection
Sampling
method
Survey
name (if
applicable)
Recruitment
location Definition of prescription opioid “misuse”
Age
category
Sample
size
Prevalence
N, % 95% Cis
Becker, Sullivan,
Tetrault, Desai,
and Fiellin (2008)
2002–2004 Probability NSDUHa Households NSDUH definitiong 21–25 year
olds
21,826 2186
(10.0%)
9.6–10.4%
Berenson and
Rahman (2011)
2008–2010 Convenience .. Health
clinic
“Have you ever, even once, used a prescription
pain reliever that was not prescribed for you or
that you took only for the experience or feeling
it caused?” [NSDUH informed question]
16–24 year
olds
2976 20 (0.7%) 0.4–1.0%
Boyd, Young, Grey,
and McCabe
(2009)
2007 Convenience … Educational
setting
Nonmedical use was measured with the
question: “On how many occasions in the past
12 months have you used the following types
of drugs not prescribed to you?”
13–15 year
olds
912 91 (10.0%) 8.1–12.1%
Boyd, McCabe,
Cranford, and
Young (2007)
2005 Convenience .. Educational
setting
Use of prescription medication to “get high”, to
create an altered states, or for reasons (or by
routes) other than what the prescribing
clinician intended.
11–13 year
olds
290 20 (6.9%) 4.3–10.5%
14–16 year
olds
580 74 (12.8%) 10.2–15.8%
17–19 year
olds
214 32 (15.0%) 10.5–20.4%
Cerda et al. (2014) 2010 Convenience GUTSb Multi-site “Have you ever used pain killers (e.g., Percocet,
Percodan, Oxycontin, Oxycodone, codeine,
morphine) without a doctor's prescription?”
23–30 year
olds
7646 543 (7.1%) 6.5–7.7%
Fiellin et al. (2013) 2006–2008 Probability NSDUHa Households NSDUH definition 18–19 year
olds
15,079 1916
(12.7%)
12.2–13.2%
20–21 year
olds
13,602 1696
(12.5%)
11.9–13.0%
22–23 year
olds
13,363 1534
(11.5%)
10.9–12.0%
24–25 year
olds
13,171 1350
(10.3%)
9.7–10.8%
Jones (2013) 2002–2004 Probability NSDUHa Households NSDUH definition 12–17 year
olds
24,987 1860
(7.4%)
7.1–7.8%
18–25 year
olds
31,648 3679
(11.6%)
11.3–12.0%
2008–2010 Probability NSDUHa Households NSDUH definition 12–17 year
olds
24,617 1553
(6.3%)
6.0–6.6%
18–25 year
olds
33,531 3758
(11.2%)
10.1–11.6%
Lord, Brevard, &
Budman (2011)
2005 Convenience .. Social
network
website
“Which of the following prescription pain
medications have you ever used for nonmedical
reasons? Nonmedical means use of a prescription
drug without a prescription or for reasons other
than those indicated by a prescription”
18–25 year
olds
527 86 (16.3%) 13.3–19.8%
Martins et al.
(2012)
2004–2005 Probability NESARCd Households NESARC definitionh 18–29 year
olds
6719 261 (3.9%) 3.4–4.4%
McCabe, Teter,
Boyd, Knight,
and Wechsler
(2005)
2001 Systematic CASc Educational
setting
“How often, if ever, have you used any of the
drugs listed below? Do now include anything
you used under a doctor's orders.” [list of pain
killers]
b21 years
old
5444 387 (7.1%) 6.4–7.8%
21–23 year
olds
3959 281 (7.1%) 6.3–7.9%
McCabe et al.
(2005)
2000–2002 Probability NESARCd Households NESARC definition 17–24 year
olds
5198 236 (4.5%) 4.0–5.1%
McCabe, West,
Morales et al.
(2007), McCabe,
West and
Wechsler, (2007)
1993 Systematic CASc Educational
setting
“How often, if ever, have you used any of the
drugs listed below? Do now include anything
you used under a doctor's orders.” [list of pain
killers]
18–24 year
olds
15,282 474 (3.1%) 2.8–3.4%
1997 Systematic CASc Educational
setting
18–24 year
olds
14,428 544 (3.8%) 3.5–4.1%
1999 Systematic CASc Educational
setting
18–24 year
olds
13,953 629 (4.5%) 4.2–4.9%
2001 Systematic CASc Educational
setting
18–24 year
olds
10,904 800 (7.3%) 6.9–7.8%
McCabe, West,
Teter, and Boyd
(2012)
2002–2006 Probability MTFe Educational
setting
“Used prescription opioids on their own-that is,
without a doctor telling them to take the
medicine (e.g., Vicodin, Percodan)”
17–18 year
olds
11,274 843 (7.5%) 7.0–8.0%
McCabe, West, and
Boyd (2013a,
2013b)
2007–2010 Probability MTFe Educational
setting
“Used prescription opioids on their own-that is,
without a doctor telling them to take the
medicine (e.g., Vicodin, Percodan)”
17–18 year
olds
8888 647 (7.3%) 6.7–7.8%
Nakawaki and
Crano (2012)
2003–2009 Probability NSDUHa Households NSDUH definition 12–17 year
olds
126,764 11,521
(12.0%)
11.8–12.2%
Sung et al., 2005 2005 Probability NSDUHa Households NSDUH definition 14–15 year
olds
6000 450 (7.5%) 6.8–8.2%
16–17 year
olds
5554 661
(11.9%)
11.1–12.7%
Tetrault et al.
(2008)
2003 Probability NSDUHa Households NSDUH definition 19–23 year
olds
11,371 1341
(11.8%)
11.2–12.4%
24–34 year
olds
5228 749
(14.3%)
13.4–15.3%
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Table 1 (continued)
Report
Year of
data
collection
Sampling
method
Survey
name (if
applicable)
Recruitment
location Definition of prescription opioid “misuse”
Age
category
Sample
size
Prevalence
N, % 95% Cis
Wu et al., (2008) 2005–2008 Probability NSDUHa Households NSDUH definition 14–15 year
olds
12,682 799 (6.3%) 5.9–6.7%
16–17 year
olds
12,445 1394
(11.2%)
10.7–11.8%
Zullig and Divin
(2012)
2008 Probability NCHAf Educational
setting
“Have you taken any of the following prescription
drugs that were not prescribed to you?” [list of
painkillers (e.g., OxyCotin, Vicodin)]
≤25 year
olds
22,783 1913
(8.4%)
8.0–8.9%
a National Survey on Drug Use and Health (NSDUH).
b Growing Up Today Study (GUTS).
c College Alcohol Survey (CAS).
d National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
e Monitoring the Future (MTF).
f National College Health Assessment (NCHA).
g NSDUH definition: “Have you ever, even once, used a prescription pain reliever that was not prescribed for you or that you took only for the experience or feeling it caused?”
h NESARC definition: “Now I'd like to ask you about your experiences with medicines and other kinds of drugs that you may have used on your own-that is, either without a doctor's
prescription (pause); in greater amounts, more often, or longer than prescribed (pause); or for a reason other than a doctor said you should use them. People use these medicines and
drugs on their own to feel more alert, to relax, or quiet their nerves, to feel better, to enjoy themselves, or to get high, or just to see how they would work.”
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Among the 34 estimates contributing to the analysis of the change in
prevalence of prescription opioid misuse over time, the majority (31 of
34) present data from 2001 to 2010. For the data characterizing pre-
scription opioid misuse prevalence (all sampling methods), prevalence
over the years of data collection (from 1993 through to 2010) was
shown to increase by 0.40% (p-value b0.001) each year. Similar statisti-
cally significant increases in prevalence over time were also observed
among those reports using probability and non-probability sampling
methods (0.25% and 0.05%, respectively; p-values b0.000).4. Discussion
The results of this systematic review and meta-analysis which in-
cluded 34 independent estimates from 503,845 unique persons aged
11–30 years in the US, demonstrate a high and rising prevalence of
past-year prescription opioid misuse. Reports presenting data from
probability-based surveys identified amore narrow range of prevalence
(range interval spanned 8.8 units) than did reports relying on non-Fig. 2. Prevalence of past-year prescription opioprobability samples (range interval spanned 15.6). That the probability
samples presented a narrower prevalence estimates was likely due to
the large sample sizes compared to the non-probability samples.
A keyfindingof thismeta-analysiswas the statistically significant in-
crease in the prevalence of prescription opioidmisuse among those 11–
30 years of age from 1993 through 2010. The rise in prevalence we ob-
served is consistent with a National Institute of Drug Abuse report
documenting a rise in the incidence of prescription opioid misuse over
the period 1994–2001 (CEWG, 2005). These rates rose from approxi-
mately 12–13 per 1000 persons for those aged 12–17 years and 18–
25 years to nearly 50 per 1000 among 12–17 year olds and to over 30
for those in the 18–25 age group in 2001 (CEWG, 2005). In 2014, nation-
al estimates for past 30-day prescription opioid misuse among those in
the age groups 12–17 and 18–25 were lower than estimates from the
time period 2002–2012; however, similar to the 2013 estimates
(NSDUH, 2014).
There have been several efforts to address the prescription opioid
misuse epidemic in the US. These efforts have included strategies to in-
crease the use of tamper-resistant pill containers to avoid diversion to
adolescents and others, and interventions at the provider level
(Gilson, Fishman, Wilsey, Casamalhuapa, & Baxi, 2012; Griggs &id misuse among those 11–30 years of age.
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itoring systems (Brady et al., 2014) and improved guidelines for the use
of prescription opioids (Manchikanti et al., 2012). There have also been
efforts to develop prescription opioids that resist being rendered into a
form that is easily inhaled or injected (Romach, Schoedel, & Sellers,
2013). Regulating prescription opioidsmore tightly, andmaking formu-
lations less readily injectable, in the absence of easy access to drug treat-
ment, may unintentionally accelerate the transition to heroin injection
drug use among already dependent persons (Cicero, Ellis, & Surratt,
2012; Mars, Bourgois, Karandinos, Montero, & Ciccarone, 2014).
The critical importance of addressing drug dependence in adoles-
cents and young adulthood cannot be understated. Use and misuse of
prescription opioids at younger ages has been found to be associated
with a higher likelihood of a diagnosis of opioid abuse/dependence.
Edlund et al. demonstrated a strong inverse relationship between age
and post-misuse opioid abuse/dependence, where a particularly high
likelihood of opioid abuse/dependence diagnoses were found among
those aged 18–30 compared to those over 65 years (OR = 9.08, 95% CI
3.38–24.1) (Edlund et al., 2010). A national sample reported that 36%
of adolescents 12–17 years misusing prescription drugs (including opi-
ates, stimulants and tranquilizers/sedatives) exhibited one or more
signs of dependence including tolerance, spending a great deal of time
acquiring, using or recovering from the drug, and experiencing with-
drawal (Schepis & Krishnan-Sarin, 2008).
Early intervention is key to preventing the development of depen-
dence and abuse among all misusers, but there is greater urgency for
prioritizing early intervention among youngpeople. Public health policy
must effectively and systematically address the availability and accessi-
bility of evidence-based treatment of opioid abuse and dependence
(e.g., methadone and buprenorphine) to respond to the current opioid
epidemic (Maremmani & Gerra, 2010; Perlman et al., 2015). Programs
to prevent fatal overdoses, such as naloxone distribution programs,
are critical in addressing preventable drug use-related deaths (CDC,
2012b). Transition to heroin is an additional and key concern related
particularly to misuse of prescription opioids; heroin use has increased
in the US by 145% since 2007, and fatal overdoses due to heroin have in-
creased 5-fold during the same time period (NSDUH, 2014).
4.1. Limitations
Several important limitations to our study are worth mentioning.
First, both the generalizability and validity of our pooled estimate are
dependent on the quality of the data provided in each individual report,
thus, we were only able to present prevalence ranges. In order to ac-
count for the varying quality of individual estimates we employed an
NOS-informed quality rating scale to assess study-level quality and ex-
plored the effect of study quality on prevalence in moderator analysis.
We found that prevalence did not varymeaningfully in relation to qual-
ity assessment scores.
While we were able to document an ongoing increase in prevalence
among those aged 11–30 from the 1990s to 2010, we were not able to
examine trends in specific age groups across reports because of incon-
sistencies in the way age groups were constructed in the included re-
ports. However, Sung, et al. demonstrated both an increase in lifetime
misuse prevalence and in the number of new misusers among youth
aged 12–17 from 1968 to 2002 (Sung, Richter, Vaughan, Johnson, &
Thom, 2005).
In moderator analysis we were able to explore the role of year of
data collection on prevalence. One limitation regarding categorizing cal-
endar year was that it relied on interpolation for half of the estimates
and thus, may have introduced error in the observed trends in preva-
lence of past-year prescription opioidmisuse over time. However, as al-
ready discussed, the observed increase in prevalence over time is
consistent with other published data not included in this report
(CEWG, 2005; Imtiaz et al., 2014). Another potential limitation is that
the included reports used a variety of different definitions ofprescription opioid misuse (based on slightly different questions of
those surveyed); because of inconsistencies in definitions we were un-
able to formally examine the potential contribution of differential clas-
sification to heterogeneity in prevalence estimates. This highlights the
need for consistency in definitions in future studies to ensure that esti-
mates are reliable and valid (DeVellis, 2012). In addition, we were not
able to prevalence over time either among specific age strata or geo-
graphic region or urban, suburban, or rural classification because data
available in the reports were not provided in formats allowing these
analyses. Thesewould be important areas for future research and public
health monitoring.
Lastly, the estimates used in ourmeta-analysis are only as reliable as
the estimates provided in the included studies. However, effort was un-
dertaken both through rigorously applied inclusion criteria and quality
ratings assessments to ensure that the estimates ultimately used in
analyses were of the highest quality and as reliable as possible.
5. Conclusion
Our data confirm both a high and a rising prevalence of past-year
prescription opioid misuse among those 11–30 years of age in the Unit-
ed States. This rising prevalence is an urgent public health problem the
response to which requires effort to expand access to and engagement
in evidence-based prevention and treatment interventions such as opi-
oid agonist treatment of drug dependence, sterile syringe and injection
equipment access, and efforts to reduce misuse and diversion of pre-
scription opioids.
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